Egis intensifies its acquisition strategy

6 November 2017
servier-big

Egis Pharmaceuticals, French independent drugmaker Servier’s generics company, has acquired Sorbifer’s (ferrous sulfate + ascorbic acid) product rights from AstraZeneca (LSE: AZN). The transaction reinforces Egis’ position on its key markets.

Egis, of which Servier gained full ownership in a deal worth around $483 million in 2013, has already been producing, distributing and promoting Sorbifer in 18 Central and Eastern Europe (CEE) and Commonwealth of Independent States (CIS) markets since 1985 under a licence agreement with Anglo-Swedish pharma major AstraZeneca. The product has become one of the major brands of Egis, the fifth largest of the company.

Sorbifer is an anti-anemia prescription drug, which has a strong position in the CEE and CIS markets, particularly in Russia and Poland.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical